Ocular Behçet’s Disease: Changing Patterns Over Time, Complications and Long-Term Visual Prognosis

REFERENCES

• Behçet H. Uber rezidivieerende aphtose, durch ein virus verursachte geschwure am mund, an auge und an den genitalien. Dermatol Wochenschr. 1937;105:1152–1157.
   Google Scholar
• International Study group for Behçet’s disease: Criteria for diagnosis of Behçet’s disease. Lancet 1990;335:1078–1080.
   PubMed Web of Science ®Google Scholar
• Khairallah M, Accorinti M, Muccioli C, et al. Epidemiology of Behçet’s disease. Ocul Immunol Inflamm. 2012;20:324–335.
   PubMed Web of Science ®Google Scholar
• Zafirakis P, Foster SC. Adamantiades-Behçet’s disease. In: Foster SC and Vitale AT, eds. Diagnosis and Treatment of Uveitis. Jaypee Med Pub, New Delhi; 2013: 858–886.
   Google Scholar
• Vannozzi L, Menchini U, Accorinti M. Ocular involvement and Behçet’s disease. In: Emmi L, Ed. Behçet’s syndrome, Rare Diseases of the Immune System. Springer-Verlag, Italy. 2014:97–115.
   Google Scholar
• Mamo JG, Azzam SA. Treatment of Behçet’s disease with chlorambucil. Arch Ophthalmol. 1970;84:446–450.
   PubMed Web of Science ®Google Scholar
• Zierhut M, Abu El-Asrar A, Bodaghi B, et al. Therapy of ocular Behçet disease. Ocul Immunol Inflam. 2014;22:64–76.
   PubMed Web of Science ®Google Scholar
• Shimizu T., Ehrlich GE, Inaba G, et al. Behçet’s disease. Sem Arthr Rheum. 1979;8:223–260.
   PubMed Web of Science ®Google Scholar
• The Standardization of Uveitis Nomenclature (SUN) working group: Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Pivetti-Pezzi P, Accorinti M, La Cava M, et al. Ocular features of Behçet’s disease in Italy. In: Godeau P, Wechsler B Eds. Behçet’s Disease. Elsevier Science Publ, Amsterdam; 1993:615–618.
   Google Scholar
• Kitachi N, Miyazaki A, Iwata D, et al. Ocular features of Behçet’s disease: an international collaborative study. Br J Ophthalmol. 2007;91:1579–1582.
   PubMed Web of Science ®Google Scholar
• Taylor SR, Singh J, Menezo V, et al. Behçet’s disease: visual prognosis and factors influencing the development of visual loss. Am J Ophthalmo.l 2011;152;1059–1066.
   Google Scholar
• Kazokoglu H, Onal S, Tugal-Tutkun I, et al. Demographic and clinical features of uveitis in tertiary centers in Turkey. Ophthalmic Epidemiol. 2008;15:285–293.
   PubMed Web of Science ®Google Scholar
• Direskeneli H, Mumcu G. A possible decline in the incidence and severity of Behçet’s disease: implications for an infectious etiology and oral health. Clin Exp Rheumatol. 2010; 28:86–90.
   Web of Science ®Google Scholar
• Cingu AK, Onal S, Urgancioglu M, et al. Comparison of presenting features and three-year disease course in Turkish patients with Behçet uveitis who presented in the early 1990s and the early 2000s. Ocul Immunol Inflamm. 2012;20:423–428.
   PubMed Web of Science ®Google Scholar
• Kump LI, Moeller KL, Reed GF, et al. Behçet’s disease: comparing 3 decades of treatment response at the National Eye Institute. Can J Ophthalmol. 2008;43:468–472.
   PubMed Web of Science ®Google Scholar
• Yoshida A., Kawashima H, Kotoyama Y, et al. Comparison of patients with Behçet’s disease in the 1980s and 1990s. Ophthalmology 2004;111:810–815.
   PubMed Web of Science ®Google Scholar
• Pivetti-Pezzi P., Gasparri V, De Liso P, et al. Prognosis in Behçet’s disease. Ann Ophthalmol. 1985;17:20–25.
   PubMedGoogle Scholar
• Khairralah M, Attia S, Yahia SB, et al. Pattern of uveitis in Behçet’s disease in a referral center in Tunisia, North Africa. Int Ophthalmol. 2009;29:135–141.
   PubMedGoogle Scholar
• Deuter CME, Zierhut M, Mohle A, et al. Long-term remission after cessation of interferon-a treatment in patients with severe uveitis due to Behçet’s disease. Arthritis Rheum. 2012;62:2796–2805.
   Web of Science ®Google Scholar
• Accorinti M, Pirraglia MP, Paroli MP, et al. Infliximab treatment of ocular and extracoular manifestations of Behçet’s disease. Jpn J Ophthalmol. 2007;51:191–196.
   PubMed Web of Science ®Google Scholar
• Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behçet’s syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003;82:60–76.
   PubMed Web of Science ®Google Scholar
• Pivetti-Pezzi P. Behçet’s Disease in 1988. In: Ferraz de Oliveira LN ed. Ophtalmology Today. Elsevier Sc Publ, New York; 1988:81–93.
   Google Scholar
• Arevalo FJ, Lasave AF, Al Jindan YA et al. Uveitis in Behçet Disease in a tertiary center over 25 years: the KKESH uveitis survey study group. Am J Ophthalmol. 2015; 159;177–184.
   Web of Science ®Google Scholar
• Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behçet’s disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138:373–380.
   PubMed Web of Science ®Google Scholar
• Kaçmaz RO, Kempen JH, Newcomb C, et al. Systemic immunosuppressive therapy for eye disease cohort study group. Ocular inflammation in Behçet’s disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol. 2008;146:828–836.
   PubMed Web of Science ®Google Scholar
• Kim DY, Choi MJ, Cho S, et al. Changing clinical expression of Behçet’s disease in Korea during three decades (1983-2012): chronological analysis of 3674 hospital based patients. Br J Dermato.l 2014;170:458–461.
   PubMed Web of Science ®Google Scholar
• Ando K, Fujino Y, Hijikata K et al. Epidemiological features and visual prognosis of Behçet’s disease. Jpn J Ophthalmol. 1999;43;312–317.
   Web of Science ®Google Scholar
• Chung YR, Lee ES, Kim MH, et al. Changes in ocular manifestations of Behçet’s disease in Korean patients over time: a single center experience in the 1990s and 2000s. Ocul Immunol Inflamm. 2015;23:157–161.
   PubMed Web of Science ®Google Scholar
• Davatchi F, Shahram F, Chams-Davatchi C, et al. Behçet’s disease in Iran: analysis of 6500 cases. Int J Rheum Dis. 2010;13:367–373.
   PubMed Web of Science ®Google Scholar
• Saleh OA, Birnbaum AD, Tessler HH, et al. Behçet uveitis in the American Midwest. Ocul Immunol Inflamm. 2012;20;12–17.
   Web of Science ®Google Scholar
• Tugal-Tutkun I. Behçet’s uveitis. Middle East African J Ophthalmol. 2009;16:219–224.
   PubMedGoogle Scholar
• Ucar-Comlekoglu D, Fox A, Sen NH. Gender differences in Behçet’s disease associated uveitis. J Ophthalmol. Epub 2014 Apr 23.
   Google Scholar
• Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease: an open-label trial. Arthr Rheum. 2005;52;2478–2484.
   Google Scholar
• Okada AA, Goto H, Ohno S, et al. Multicenter study of infliximab for refractory uveoretinitis in Behçet Disease. Arch Ophthalmol. 2012;130:592–598.
   PubMed Web of Science ®Google Scholar